Compile Data Set for Download or QSAR
maximum 50k data
Found 2000 with Last Name = 'wen' and Initial = 'l'
TargetDual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM168129(US9073936, 4 | US9598426, 4)
Affinity DataKi:  0.100nMAssay Description:Assay: The following phosphodiesterase enzymes may be used: 3′,5′-cyclic-nucleotide-specific bovine brain phosphodiesterase (Sigma, St. L...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetDual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM168129(US9073936, 4 | US9598426, 4)
Affinity DataKi:  0.100nM ΔG°:  -58.0kJ/molepH: 7.5 T: 2°CAssay Description:Materials: All chemicals are available from Sigma-Aldrich (St. Louis, Mo.) except for IMAP reagents (reaction buffer, binding buffer, FL-GMP and IMAP...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetDual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM168126(US9073936, 1 | US9598426, 1)
Affinity DataKi:  0.200nMAssay Description:Assay: The following phosphodiesterase enzymes may be used: 3′,5′-cyclic-nucleotide-specific bovine brain phosphodiesterase (Sigma, St. L...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetDual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM168126(US9073936, 1 | US9598426, 1)
Affinity DataKi:  0.200nM ΔG°:  -56.3kJ/molepH: 7.5 T: 2°CAssay Description:Materials: All chemicals are available from Sigma-Aldrich (St. Louis, Mo.) except for IMAP reagents (reaction buffer, binding buffer, FL-GMP and IMAP...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50048803(5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)et...)
Affinity DataKi:  0.280nMAssay Description:Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetDual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM168128(US9073936, 3 | US9598426, 3)
Affinity DataKi:  0.300nMAssay Description:Assay: The following phosphodiesterase enzymes may be used: 3′,5′-cyclic-nucleotide-specific bovine brain phosphodiesterase (Sigma, St. L...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetDual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM168128(US9073936, 3 | US9598426, 3)
Affinity DataKi:  0.300nM ΔG°:  -55.3kJ/molepH: 7.5 T: 2°CAssay Description:Materials: All chemicals are available from Sigma-Aldrich (St. Louis, Mo.) except for IMAP reagents (reaction buffer, binding buffer, FL-GMP and IMAP...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetDual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM168129(US9073936, 4 | US9598426, 4)
Affinity DataKi:  0.400nM ΔG°:  -54.5kJ/molepH: 7.5 T: 2°CAssay Description:Materials: All chemicals are available from Sigma-Aldrich (St. Louis, Mo.) except for IMAP reagents (reaction buffer, binding buffer, FL-GMP and IMAP...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetDual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM168129(US9073936, 4 | US9598426, 4)
Affinity DataKi:  0.400nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetDual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM168127(US9073936, 2 | US9598426, 2)
Affinity DataKi:  0.5nM ΔG°:  -54.0kJ/molepH: 7.5 T: 2°CAssay Description:Materials: All chemicals are available from Sigma-Aldrich (St. Louis, Mo.) except for IMAP reagents (reaction buffer, binding buffer, FL-GMP and IMAP...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetDual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM168127(US9073936, 2 | US9598426, 2)
Affinity DataKi:  0.5nMAssay Description:Assay: The following phosphodiesterase enzymes may be used: 3′,5′-cyclic-nucleotide-specific bovine brain phosphodiesterase (Sigma, St. L...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50001885((risperidone)3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-...)
Affinity DataKi:  0.5nMAssay Description:Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50007659(CHEMBL3233142)
Affinity DataKi:  0.540nMAssay Description:Displacement of [125]DOI from human recombinant full length 5HT2A receptor expressed in HEK293E cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(2) dopamine receptor(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM21398(4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1...)
Affinity DataKi:  0.700nMAssay Description:Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors.More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50007666(CHEMBL3233432)
Affinity DataKi:  0.890nMAssay Description:Displacement of [125]DOI from human recombinant full length 5HT2A receptor expressed in HEK293E cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50007667(CHEMBL3233143)
Affinity DataKi:  0.940nMAssay Description:Displacement of [125]DOI from human recombinant full length 5HT2A receptor expressed in HEK293E cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHistamine H1 receptor(Homo sapiens (Human))
Intra-Cellular Therapies

Curated by ChEMBL
LigandPNGBDBM50001884(2-[4-(4-Methyl-benzyl)-piperazin-1-yl]-1-(2-methyl...)
Affinity DataKi:  1nMAssay Description:Inhibition of histamine H1 receptor (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMedDrugBank

TargetDual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM168126(US9073936, 1 | US9598426, 1)
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50007662(CHEMBL3233427)
Affinity DataKi:  1nMAssay Description:Displacement of [125]DOI from human recombinant full length 5HT2A receptor expressed in HEK293E cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM168126(US9073936, 1 | US9598426, 1)
Affinity DataKi:  1nM ΔG°:  -52.2kJ/molepH: 7.5 T: 2°CAssay Description:Materials: All chemicals are available from Sigma-Aldrich (St. Louis, Mo.) except for IMAP reagents (reaction buffer, binding buffer, FL-GMP and IMAP...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistone H1.0(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50001884(2-[4-(4-Methyl-benzyl)-piperazin-1-yl]-1-(2-methyl...)
Affinity DataKi:  1nMAssay Description:Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50007718(CHEMBL3233430)
Affinity DataKi:  1.10nMAssay Description:Displacement of [125]DOI from human recombinant full length 5HT2A receptor expressed in HEK293E cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50007665(CHEMBL3233431)
Affinity DataKi:  1.30nMAssay Description:Displacement of [125]DOI from human recombinant full length 5HT2A receptor expressed in HEK293E cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(2) dopamine receptor(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50130293(7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}...)
Affinity DataKi:  1.60nMAssay Description:Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors.More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50007661(CHEMBL3233423)
Affinity DataKi:  1.70nMAssay Description:Displacement of [125]DOI from human recombinant full length 5HT2A receptor expressed in HEK293E cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHistone H1.0(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM35254(2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3...)
Affinity DataKi:  2nMAssay Description:Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHistamine H1 receptor(Homo sapiens (Human))
Intra-Cellular Therapies

Curated by ChEMBL
LigandPNGBDBM35254(2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3...)
Affinity DataKi:  2nMAssay Description:Inhibition of histamine H1 receptor (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMedDrugBank

Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50007668(CHEMBL3233144)
Affinity DataKi:  2.10nMAssay Description:Displacement of [125]DOI from human recombinant full length 5HT2A receptor expressed in HEK293E cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetAlpha-1A adrenergic receptor(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50001885((risperidone)3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-...)
Affinity DataKi:  2.30nMAssay Description:Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors.More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50007680(CHEMBL3233409)
Affinity DataKi:  2.40nMAssay Description:Displacement of [125]DOI from human recombinant full length 5HT2A receptor expressed in HEK293E cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM35254(2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3...)
Affinity DataKi:  2.5nMAssay Description:Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50007683(CHEMBL3233412)
Affinity DataKi:  2.5nMAssay Description:Displacement of [125]DOI from human recombinant full length 5HT2A receptor expressed in HEK293E cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM35254(2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3...)
Affinity DataKi:  2.5nMAssay Description:Displacement of [125]DOI from human recombinant full length 5HT2A receptor expressed in HEK293E cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50007663(CHEMBL3233429)
Affinity DataKi:  2.90nMAssay Description:Displacement of [125]DOI from human recombinant full length 5HT2A receptor expressed in HEK293E cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetReplicase polyprotein 1ab(Human SARS coronavirus (SARS-CoV) (Severe acute re...)
University of Bonn

LigandPNGBDBM429243(jm5b01461, Compound 60)
Affinity DataKi:  3nMAssay Description:This is a review article.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50007682(CHEMBL3233411)
Affinity DataKi:  3.30nMAssay Description:Displacement of [125]DOI from human recombinant full length 5HT2A receptor expressed in HEK293E cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50007673(CHEMBL3233149)
Affinity DataKi:  3.5nMAssay Description:Displacement of [125]DOI from human recombinant full length 5HT2A receptor expressed in HEK293E cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Vertex Pharmaceuticals

LigandPNGBDBM24601(Benzimidazole urea analogue, 5 | N-cyclopropyl-1-{...)
Affinity DataKi: <4nMAssay Description:Enzymatic hydrolysis of ATP to ADP was coupled to the conversion of NADH to NAD+. The decrease in NADH absorbance was monitored at 340 nm for 20 min ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Vertex Pharmaceuticals

LigandPNGBDBM24606(Benzimidazole urea analogue, 10 | methyl 2-[(ethyl...)
Affinity DataKi: <4nMAssay Description:Enzymatic hydrolysis of ATP to ADP was coupled to the conversion of NADH to NAD+. The decrease in NADH absorbance was monitored at 340 nm for 20 min ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50007672(CHEMBL3233148)
Affinity DataKi:  4nMAssay Description:Displacement of [125]DOI from human recombinant full length 5HT2A receptor expressed in HEK293E cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM168128(US9073936, 3 | US9598426, 3)
In DepthDetails US Patent
TargetDual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM168127(US9073936, 2 | US9598426, 2)
In DepthDetails US Patent
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Vertex Pharmaceuticals

LigandPNGBDBM24608(3-ethyl-1-[7-(1H-pyrazol-1-yl)-5-(pyridin-3-yl)-1H...)
Affinity DataKi: <4nMAssay Description:Enzymatic hydrolysis of ATP to ADP was coupled to the conversion of NADH to NAD+. The decrease in NADH absorbance was monitored at 340 nm for 20 min ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Vertex Pharmaceuticals

LigandPNGBDBM24609(3-ethyl-1-[7-(pyridin-2-yl)-5-(pyridin-3-yl)-1H-1,...)
Affinity DataKi: <4nMAssay Description:Enzymatic hydrolysis of ATP to ADP was coupled to the conversion of NADH to NAD+. The decrease in NADH absorbance was monitored at 340 nm for 20 min ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Vertex Pharmaceuticals

LigandPNGBDBM24611(3-ethyl-1-[7-(3-fluoropyridin-2-yl)-5-(pyridin-3-y...)
Affinity DataKi: <4nMAssay Description:Enzymatic hydrolysis of ATP to ADP was coupled to the conversion of NADH to NAD+. The decrease in NADH absorbance was monitored at 340 nm for 20 min ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Vertex Pharmaceuticals

LigandPNGBDBM24614(3-ethyl-1-[7-(1H-pyrazol-1-yl)-5-(pyrimidin-5-yl)-...)
Affinity DataKi: <4nMAssay Description:Enzymatic hydrolysis of ATP to ADP was coupled to the conversion of NADH to NAD+. The decrease in NADH absorbance was monitored at 340 nm for 20 min ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Vertex Pharmaceuticals

LigandPNGBDBM24615(Benzimidazole urea analogue, 19 | N-cyclopropyl-1-...)
Affinity DataKi: <4nMAssay Description:Enzymatic hydrolysis of ATP to ADP was coupled to the conversion of NADH to NAD+. The decrease in NADH absorbance was monitored at 340 nm for 20 min ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Vertex Pharmaceuticals

LigandPNGBDBM24616(1-(6-(4-(Cyclopropylcarbamoyl)-1H-imidazol-1-yl)-4...)
Affinity DataKi: <4nMAssay Description:Enzymatic hydrolysis of ATP to ADP was coupled to the conversion of NADH to NAD+. The decrease in NADH absorbance was monitored at 340 nm for 20 min ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Vertex Pharmaceuticals

LigandPNGBDBM24617(3-ethyl-1-[7-(3-fluoropyridin-2-yl)-5-(1-methyl-2-...)
Affinity DataKi: <4nMAssay Description:Enzymatic hydrolysis of ATP to ADP was coupled to the conversion of NADH to NAD+. The decrease in NADH absorbance was monitored at 340 nm for 20 min ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM168127(US9073936, 2 | US9598426, 2)
Affinity DataKi:  4nM ΔG°:  -48.7kJ/molepH: 7.5 T: 2°CAssay Description:Materials: All chemicals are available from Sigma-Aldrich (St. Louis, Mo.) except for IMAP reagents (reaction buffer, binding buffer, FL-GMP and IMAP...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 2000 total ) | Next | Last >>
Jump to: